 |
 |
Hi Gang, I looked on the news wire and found this press release.... JUNE 18, 1999 DRAXIS Acquires Canadian Rights To Eight Neurology Products From Elan - Elan Takes Equity Stake In DRAXIS SNIP DRAXIS Pharmaceutica, DRAXIS' Canadian marketing division, will assume responsibility for the marketing and selling of these products in Canada. DRAXIS Pharmaceutica already markets a range of products for Parkinson's disease and recently launched Alertec(R), the first new treatment to be launched for narcolepsy in 40 years. SNIP Zelapar(TM) Zelapar(TM) is a unique formulation of selegiline hydrochloride that rapidly dissolves in the mouth facilitating use for many Parkinson's disease patients. It is currently approved in the UK and is in Phase III trials in the United States. DRAXIS Pharmaceutica already markets Eldepryl(R), Novo-Selegiline and Permax(R) for Parkinson's disease. murray [log in to unmask]